40 studies found for:    mononucleosis
Show Display Options
Rank Status Study
21 Completed LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Condition: Nasopharyngeal Carcinoma
Intervention: Genetic: Genetically modified CTLs
22 Terminated Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
Conditions: Hodgkins Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES;   Genetic: LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
23 Terminated Vaccination With Tetanus and KLH to Assess Immune Responses.
Condition: Cancer
Interventions: Biological: Intracel KLH Vaccine;   Biological: Biosyn KLH;   Drug: Montanide ISA51;   Biological: Tetanus toxoid
24 Recruiting Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Conditions: Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
Intervention: Biological: MABEL CTLs
25 Recruiting Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Lymphoproliferative Disorder;   Nasopharyngeal Carcinoma;   Leiomyosarcoma;   Severe Chronic Active EBV (SCAEBV)
Intervention: Biological: LMP specific T cells
26 Active, not recruiting LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Conditions: Hodgkin Disease;   Non Hodgkin Lymphoma;   Lymphoepithelioma;   Leiomyosarcoma
Interventions: Biological: LMP1/2 CTLs (Group A);   Biological: LMP1/2 CTLs (Group B);   Biological: LMP1/2 CTLs (Group C)
27 Recruiting Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
Conditions: Hodgkin Disease;   Non Hodgkin Lymphoma;   Lymphoepithelioma;   Severe Chronic Active EBV Infection Syndrome (SCAEBV);   Leiomyosarcoma
Interventions: Drug: LMP1/2 CTLs (Group A);   Drug: LMP1/2 CTLs (Group B)
28 Completed Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus
Conditions: Epstein Barr Virus Infection;   Healthy
Intervention:
29 Active, not recruiting Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel;   Drug: Carboplatin;   Drug: Dexamethasone;   Biological: EBV-specific cytotoxic T lymphocytes
30 Terminated LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)
Condition: Lymphoma
Interventions: Biological: CD45 antibodies;   Biological: EBV specific T cells
31 Active, not recruiting T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Genetic: autologous or syngeneic PBTLs and EBV-CTLs
32 Active, not recruiting EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Genetic: autologous CAR.CD30 EBV specific-CTLs
33 Completed Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations
Condition: Epstein-Barr Virus Infections
Intervention:
34 Active, not recruiting Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)
Conditions: Lymphoma;   Hodgkin's Disease;   Relapse;   Lymphoma, Non-Hodgkin
Intervention: Genetic: TGFbeta resistant LMP-specific CTLs
35 Active, not recruiting Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
Condition: Neuroblastoma
Intervention: Biological: 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) w/o lymphodepletion
36 Recruiting Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Conditions: Acute Lymphoblastic Leukemia (ALL);   Chronic Lymphocytic Leukemia (CLL);   Non Hodgkin's Lymphoma
Intervention: Genetic: CD19CAR/virus specific T cells
37 Completed Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)
Condition: Epstein-Barr Virus Infections
Intervention: Biological: Intravenous injection of EBV specific CTLS
38 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
39 Completed Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
Conditions: Adenovirus Infection;   Epstein-Barr Virus Infections;   Cytomegalovirus Infections;   Stem Cell Transplant
Intervention: Biological: Multi-virus Specific T cells
40 Recruiting ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus
Condition: Viral Infection
Intervention: Biological: Multi-virus-specific cytotoxic T lymphocytes

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page   
Indicates status has not been verified in more than two years